The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation
Type 2 diabetes management: Semaglutide
A separate product, semaglutide subcutaneous injection (Wegovy), is indicated as an adjunct to lifestyle modifications for weight loss and chronic weight management in obese (BMI 30 kg/m2 or greater) or overweight adults (BMI 27 kg/m2 or greater) with at least 1 weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
When semaglutide slows gastric emptying, your stomach stays full longer
Stability data should confirm potency retention under specified storage conditions
It is the beginning of a formal regulatory process, and patients deserve to understand exactly what that difference means